A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Locally Advanced or Metastatic Solid Tumor Clinical Trial

Official title:
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Status Recruiting

Clinical Trial Summary

In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Locally Advanced or Metastatic Solid Tumor
Neoplasms

Clinical Trial Details

NCT number	NCT05194982
Study type	Interventional
Source	Sichuan Baili Pharmaceutical Co., Ltd.
Contact	Hai Zhu, PHD
Phone	+86-13980051002
Email	zhuhai@baili-pharm.com
Status	Recruiting
Phase	Phase 1
Start date	November 29, 2021
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03601897` - A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03717415` - A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05461768` - A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors	Phase 1